Champions Story

<div class='circular--portrait' style='background:#3b5998;color: #F0F8FF;font-size:4em;'>CO</div>
CSBR -- USA Stock  

USD 11.23  0.18  1.63%

While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to sum up Champions Oncology. We will analyze why it could be a much better year for Champions Oncology shareholders. Is the firm current valuation justified for 2020? Here i will cover my perspective on valuation to give Champions retail investors a better outlook on taking a position in the stock.
Published over three months ago
View all stories for Champions Oncology | View All Stories
Our prognosis on Champions Oncology (NASDAQ:CSBR) to bounce back in October
Champions Oncology currently holds 3.8 M in liabilities with Debt to Equity (D/E) ratio of 0.71, which is about average as compared to similar companies. Champions Oncology is UNDERVALUED at 8.65 per share with modest projections ahead. The company has Profit Margin (PM) of (6.15) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (4.57) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.05.
We determine the current worth of Champions Oncology using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Champions Oncology based exclusively on its fundamental and basic technical indicators. By analyzing Champions Oncology's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Champions Oncology's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Champions Oncology. We calculate exposure to Champions Oncology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Champions Oncology's related companies.

Champions Oncology Investment Alerts

Champions investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Champions Oncology performance across your portfolios.Please check all investment alerts for Champions

Champions Oncology Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Champions value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Champions Oncology competition to find correlations between indicators driving the intrinsic value of Champions.

How Champions utilizes its cash?

To perform a cash flow analysis of Champions Oncology, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Champions Oncology is receiving and how much cash it distributes out in a given period. The Champions Oncology cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Champions Oncology Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Champions Oncology reported last year Net Cash Flow from Operations of 3.34 Million

Going after Champions Financials

The entity reported the previous year's revenue of 32.12 M. Net Loss for the year was (1.98 M) with profit before overhead, payroll, taxes, and interest of 15.24 M.
 2017 2018 2019 2020 (projected)
Revenues USD20.24 M27.07 M32.12 M34.66 M
Revenues20.24 M27.07 M32.12 M34.66 M

Margins Breakdown

Champions profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Champions Oncology itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Champions Oncology profit margins.
EBITDA Margin(0.0345)
Gross Margin0.42
Profit Margin(0.0658)

Champions Oncology Average Equity is relatively stable at the moment. Also, Champions Oncology Earnings Before Interest Taxes and Depreciation Amortization EBITDA is increasing over the last 8 years.

Some Champions technical indicators suggest recoup

Latest mean deviation is at 2.75. Champions Oncology exhibits very low volatility with skewness of -0.45 and kurtosis of 0.38. However, we advise investors to further study Champions Oncology technical indicators to make sure all market info is available and is reliable.

Our Final Take On Champions Oncology

While few other entities in the biotechnology industry are either recovering or due for a correction, Champions may not be as strong as the others in terms of longer-term growth potentials. The inconsistency in the assessment between current Champions valuation and our trade advice on Champions Oncology is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Champions Oncology.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Champions Oncology. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to